Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Ashworth

Showing results (61-70 of 434) with videos related to

Pageof 44
Sort By:
Genes & Development|September 6, 2005
Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specificationBeatrice Howard, Heena Panchal, Afshan McCarthy, et al.
Nature Reviews. Drug Discovery|December 1, 2012
Tankyrase-targeted therapeutics: expanding opportunities in the PARP familyJenna L Riffell, Christopher J Lord, Alan Ashworth
Cancer Discovery|November 14, 2012
The promise of combining inhibition of PI3K and PARP as cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2010
Therapeutic targeting of the DNA mismatch repair pathwaySarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology|October 20, 2010
Synthetic lethal approaches to breast cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery|June 30, 2007
Utilizing RNA interference to enhance cancer drug discoveryElizabeth Iorns, Christopher J Lord, Nicholas Turner, et al.
Nature Clinical Practice. Oncology|August 31, 2007
Mechanisms of disease: angiogenesis and the management of breast cancerSusana Banerjee, Mitch Dowsett, Alan Ashworth, et al.
Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Nature Cell Biology|April 2, 2008
BRCA1 and stem cells: tumour typecastingMatthew J Smalley, Jorge S Reis-Filho, Alan Ashworth
Nature|May 6, 2026
Two decades of PARP inhibitor synthetic lethality in cancerChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Pageof 44

Showing results (61-70 of 434) with videos related to

Sort By:
Pageof 44
Genes & Development|September 6, 2005
Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specificationBeatrice Howard, Heena Panchal, Afshan McCarthy, et al.
Nature Reviews. Drug Discovery|December 1, 2012
Tankyrase-targeted therapeutics: expanding opportunities in the PARP familyJenna L Riffell, Christopher J Lord, Alan Ashworth
Cancer Discovery|November 14, 2012
The promise of combining inhibition of PI3K and PARP as cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2010
Therapeutic targeting of the DNA mismatch repair pathwaySarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology|October 20, 2010
Synthetic lethal approaches to breast cancer therapyFarah L Rehman, Christopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery|June 30, 2007
Utilizing RNA interference to enhance cancer drug discoveryElizabeth Iorns, Christopher J Lord, Nicholas Turner, et al.
Nature Clinical Practice. Oncology|August 31, 2007
Mechanisms of disease: angiogenesis and the management of breast cancerSusana Banerjee, Mitch Dowsett, Alan Ashworth, et al.
Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Nature Cell Biology|April 2, 2008
BRCA1 and stem cells: tumour typecastingMatthew J Smalley, Jorge S Reis-Filho, Alan Ashworth
Nature|May 6, 2026
Two decades of PARP inhibitor synthetic lethality in cancerChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Pageof 44